Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 2,761 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Activity Clear all

Conditions: Bipolar Disorder
Interventions: Transcranial Magnetic Stimulation (TMS), Sham (placebo) TMS; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 24 Years to 65 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Charlestown, Massachusetts • Philadelphia, Pennsylvania

Conditions: Bed Rest
Interventions: Leucine, Exercise, Whey protein; Dietary Supplement · Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 60 Years to 80 Years
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: End Stage Renal Disease
Interventions: CoQ10, Placebo, HB-HIIT, Observational; Dietary Supplement · Drug · Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Sacramento, California • Nashville, Tennessee

Conditions: Intellectual Disability, Developmental Disability, Axis I Diagnosis, Mental Illness, Covid19, Coronavirus
Interventions: Generic Best Practices, Tailored Best Practices; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Violence in Adolescence
Interventions: Multi-level Violence Prevention Intervention - Boys, Multi-level Violence Prevention Intervention - Caregivers; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 11 Years to 14 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Neoplasms, Solid Tumors
Interventions: aza-TdC; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Carcinoma
Interventions: Aerobic Exercise, Dietary Intervention, Quality-of-Life Assessment, Questionnaire Administration, Resistance Training; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years to 69 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine, Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 14 more

Conditions: Sexual Wellness, Women Health
Interventions: Shatavari (Asparagus racemosus) Root Extract, Placebo Capsule; Dietary Supplement · Other
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 20 Years to 50 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stroke
Interventions: tRNS (Transcranial Random Noise Stimulation), FES (Functional Electrical Stimulation)-assisted task-specific practice, Sham-tRNS (Transcranial Random Noise Stimulation); Device
Lead sponsor: University of Utah; Other
Eligibility: 40 Years to 85 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Orthodontics
Interventions: OrthoPulse, No intervention; Device · Other
Lead sponsor: Biolux Technology GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Chandler, Arizona

Conditions: Traumatic Brain Injury
Interventions: Exercise - Low-intensity exercise, Exercise - High-intensity exercise; Other
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder
Interventions: Exercise, Sitting; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Soft Contact Lenses, Myopia
Interventions: Soft Contact Lens - Daily Disposable Alcon Dailies Total 1 and ACUVUE TruEye, Soft Contact Lens - Acuvue TruEye and Alcon DAILIES TOTAL 1.; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 38 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Rumination, Major Depressive Disorder, Anxiety
Interventions: Transcranial Magnetic Stimulation; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Major Depression, Fibromyalgia
Interventions: Active TMS, Sham TMS; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Neuroendocrine Tumors
Interventions: fosbretabulin; Drug
Lead sponsor: Mateon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Stanford, California • Lexington, Kentucky • The Bronx, New York + 2 more

Conditions: Child Development, Child Language, Child Behavior Problem, Parenting, Parent Child Abuse
Interventions: Text4Baby or Bright by Text Referral, Nurture Program Warm Referral, Video Interaction Project, Family Check-UP, Smart Beginnings, Healthy Families America Warm Referral, Family Center Warm Referral; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: Up to 6 Years
Enrollment: 2,546 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Pittsburgh, Pennsylvania

Conditions: Early Ambulation
Interventions: Implementation Strategy: Foundational Support, Implementation Strategy: Enhanced Support; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Suicide, Mental Health Disorder, Anhedonia
Interventions: ViraSafe: Treatment pushes, BRITE; Behavioral
Lead sponsor: Ksana Health; Industry
Eligibility: 13 Years to 24 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Eugene, Oregon • Pittsburgh, Pennsylvania

Conditions: Depression, Systemic Lupus Erythematosus
Interventions: Chronic Disease Self-Management Program (CDSMP), Mail-delivered arthritis kit, Support group, Listserv; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Hodgkin's Lymphoma
Interventions: Tacrolimus (ARM with Methotrexate), Tacrolimus (ARM with MMF and Cyclophosphamide), Methotrexate (ARM with Maraviroc), Methotrexate (ARM with Bortezomib), Maraviroc, Bortezomib, Mycophenolate mofetil, Cyclophosphamide; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 30
States / cities: Duarte, California • Stanford, California • Gainesville, Florida + 24 more

Conditions: Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy
Interventions: SB-007; Genetic
Lead sponsor: Splice Bio; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Aurora, Colorado • Miami, Florida • Boston, Massachusetts + 2 more

Conditions: Thrombotic Microangiopathies
Interventions: OMS721; Biological
Lead sponsor: Omeros Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 5
States / cities: Duarte, California • Rochester, Minnesota • New York, New York + 2 more

Search by objective public record fields.

Intermittent Theta Burst Stimulation (iTBS) for Emotion Regulation in Bipolar Disorder

Preserving Muscle Mass and Function in Bedridden Older Adults

CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease

Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings

A Multi-level Approach to Violence Prevention Among African American Adolescents

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

Efficacy and Safety of Shatavari Root Extract in Women's Sexual Wellness

A Novel Multimodal Approach to Promote Motor Recovery and Plasticity After Stroke

Study of the Use of Orthopulse Photobiomodulation

Effects of Exercise on Memory in Healthy and Brain-Injured Individuals

Level of Physical Activity and Fear Learning

DAILIES TOTAL1 Versus ACUVUE TruEye - Effects on the Biology of the Ocular Surface and Lid Margin

Decoding and Modulating Affective Brain States

A Pilot Study of TMS Effects on Pain and Depression in Patients With Fibromyalgia

Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

The Pittsburgh Study Early Childhood

Implementing a Hospital-Based Walking Program (STRIDE): Function QUERI 2.0

A Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents

Intervention to Improve Quality of Life in African American Lupus Patients

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies